MDMA, a synthetic compound sold illicitly as ecstasy or molly, is microdosed in small repeated amounts for subtle shifts in mood, social ease or pain. No benefit rises above low confidence; documented effects come almost entirely from full doses with psychotherapy. The firmest risk is a short-lived rise in blood pressure, heart rate and body temperature; heart-valve concerns are uncertain at small doses, and illicit supply is often mislabeled. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure (seated) | <120/80 mmHg at rest; systolic <140 mmHg 60–120 min post-dose | Acute stimulant load |
| Resting heart rate | 50–70 beats/min | Acute stimulant load |
| Echocardiogram | No more than trace valve regurgitation; normal leaflet thickness | Detects 5-HT2B valve damage |
| NT-proBNP | <125 pg/mL | Early heart-strain signal |
| Serum sodium | 138–142 mmol/L | Hyponatremia risk |
| ALT | 10–25 U/L | Liver injury |
| eGFR | ≥90 mL/min/1.73 m² | Kidney clearance and fluid handling |
| CYP2D6 genotype | Normal metabolizer | Predicts MDMA accumulation |
| PHQ-9 score | 0–4 | Tracks low mood |
Cadence: Baseline before the first dose; blood pressure and heart rate 60–120 minutes after each of the first three doses, then weekly; serum sodium and liver enzymes at 4 weeks; depression questionnaire every 2 weeks; echocardiogram at 3 months, every 6–12 months if dosing continues, and once after the course ends